Patient‐level indirect treatment comparison of lanadelumab versus pdC1‐INH i.v. in hereditary angioedema patients: PATCH study
Allergy · 2024
DOI: 10.1111/all.15861 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, 2024. Verfasst von Markus Magerl und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Fraunh…. Hauptthemen laut MEDLINE: Angioedemas, Hereditary. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Takeda Pharmaceutical Company.
Abstract (Originalsprache)
Background
Hereditary angioedema (HAE) is an autosomal dominant inherited disease in which patients suffer from local attacks primarily affecting skin and gastrointestinal tract, and sometimes even the upper respiratory tract leading to asphyxiation. Since head‐to‐head trials between authorized treatments are lacking, this study compares efficacy and safety of lanadelumab and intravenous plasma‐derived C1‐esterase inhibitor (pdC1‐INH i.v.) in HAE patients on long‐term prophylaxis by means of an indirect treatment comparison.
Methods
Efficacy and safety of lanadelumab against pdC1‐INH i.v. were analyzed in a fully prespecified indirect comparison based on individual patient data ( n = 231) from the HELP and CHANGE clinical trials. Primary and secondary efficacy endpoints were compared using a generalized linear model for count data. Confounding variables were identified a priori via systematic literature research and validated by clinical experts. Adjustment of confounders was implemented using a conditional regression model.
Results
Lanadelumab showed a statistically significant improvement in reduction of HAE attack rates compared to pdC1‐INH i.v. across multiple endpoints: Monthly attack rate of patients treated with lanadelumab was less than half compared to pdC1‐INH i.v. (Rate ratio: 0.486; 95% CI: 0.253, 0.932). Monthly rate of laryngeal attacks was found to be five times lower for lanadelumab (Rate ratio: 0.2; 95% CI: 0.044, 0.915) and monthly rate of acute treated HAE attacks among lanadelumab patients was about one third of the attack rate of pdC1‐INH i.v. patients (Rate ratio: 0.366; 95% CI: 0.185, 0.727).
Conclusion
This study contributes to current knowledge in the treatment of HAE by indicating a statistically significant reduction of HAE attacks under lanadelumab compared to pdC1‐INH i.v.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immun…
- IGES Institute GmbH, Berlin, Germany.
- Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany.
- Universitätsklinikum Frankfurt, Frankfurt, Germany.
ORCID-Profile: Markus Magerl, Guido Schiffhorst, Lena Fanter, Gerrit Müller, Christoph Hirche, Fabian Berkemeier, Emel Aygören
Förderung
- Takeda Pharmaceutical Company
Zitieren
APA
Magerl, M., Schiffhorst, G., Fanter, L., Müller, G., Hirche, C., Berkemeier, F., & Aygören, E. (2024). Patient‐level indirect treatment comparison of lanadelumab versus pdC1‐INH i.v. in hereditary angioedema patients: PATCH study. Allergy. https://doi.org/10.1111/all.15861
Vancouver
Magerl M, Schiffhorst G, Fanter L, Müller G, Hirche C, Berkemeier F, et al. Patient‐level indirect treatment comparison of lanadelumab versus pdC1‐INH i.v. in hereditary angioedema patients: PATCH study. Allergy. 2024. doi:10.1111/all.15861
BibTeX
@article{Magerl2024,
author = {Magerl, Markus and Schiffhorst, Guido and Fanter, Lena and Müller, Gerrit and Hirche, Christoph and Berkemeier, Fabian and Aygören, Emel},
title = {Patient‐level indirect treatment comparison of lanadelumab versus pdC1‐INH i.v. in hereditary angioedema patients: PATCH study},
journal = {Allergy},
year = {2024},
doi = {10.1111/all.15861}
}
EUVIMED